Highlights 

  • Microbot Medical LIBERTY system adopted by Emory University Hospital 
  • First FDA-cleared, single-use, remotely operated endovascular robotic system in the world 
  • Collaboration establishes Emory’s Endovascular Robotics Program in interventional radiology 
  • LIBERTY designed to reduce clinician radiation exposure and physical strain 
  • Full market release planned at Society of Interventional Radiology (SIR) conference in April 2026 

Microbot Medical Inc. (NASDAQ:MBOT) announced that Emory University Hospital in Atlanta is the first hospital worldwide to adopt its LIBERTY® Endovascular Robotic System. LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system designed for peripheral endovascular procedures. It enables precise navigation within vascular pathways while aiming to reduce radiation exposure and physical strain on clinicians. 

The system’s adoption reflects Emory’s commitment to advancing interventional radiology and providing cutting-edge care. Microbot is collaborating with Emory to establish an Endovascular Robotics Program, integrating LIBERTY into clinical practice and supporting research into this rapidly evolving medical specialty. 

Clinical Applications and Benefits 

LIBERTY is designed for peripheral interventions including liver tumor embolization, prostate artery embolization, and uterine fibroid embolization. Its single-use design and remote operation allow for enhanced procedural control, workflow efficiency, and clinician safety. By reducing repetitive strain and radiation exposure, LIBERTY aims to improve both operational efficiency and patient outcomes. 

Dr. J. David Prologo, division director for Interventional Radiology at Emory University School of Medicine, emphasized, “Introducing innovative technologies such as LIBERTY to our interventional radiology program underscores our priority to remain at the forefront of technological advancement. Its single-use, remotely operated design offers a scalable approach to robotics that supports our operational goals, protects our clinicians, and provides access to quality care.” 

Commercial Strategy and Market Rollout 

Microbot recently commenced a limited market release of LIBERTY and is planning a full launch at the Society of Interventional Radiology conference in April 2026. This strategic rollout will allow the company to demonstrate the system’s capabilities and accelerate adoption across hospitals and specialty clinics. 

CEO Harel Gadot stated, “This is a major milestone for Microbot Medical and the surgical robotics space. We are establishing a new medical robotic category with the first FDA-cleared single-use robotic system. Emory University Hospital’s early adoption highlights enthusiasm for expanding access to innovative technology in the growing field of medical robotics.” 

Backed by an intellectual property portfolio and ongoing product development, Microbot Medical continues to focus on scaling its technology for broad adoption in endovascular care. 

Conclusion 

The adoption of LIBERTY at Emory University Hospital positions Microbot Medical at the forefront of endovascular robotic innovation. By combining advanced precision, safety, and efficiency, the system addresses critical needs in interventional radiology. With ongoing research collaborations and an upcoming full market release, Microbot is poised to redefine how minimally invasive procedures are performed worldwide. 

Also read - CollPlant (NASDAQ:CLGN) Advances Aesthetic and Regenerative Portfolio in Q3 2025 Update